"By leveraging Oncostudio AI, we have revolutionized our clinical workflows. Now, we can significantly enhance team productivity without the need for additional manpower. In particular, we've reduced the contouring task for normal organs in head and neck cancer patients from several hours to just 5 minutes. This enables tremendous time savings and facilitates faster and more efficient patient care. The ability to contour normal organs with high granularity helps in achieving personalized precision radiotherapy for patients."

"Thanks to the revolutionary improvement in the quality and speed of contouring, more sophisticated radiation therapy has become possible. We actively utilize this advancement in various clinical researches, confidently anticipating further development towards personalized precision radiotherapy in the future."

"The opportunity has arisen to change perceptions of AI in clinical settings. Currently, we provide support for normal organs, but we hope that in the future, Oncosoft's experience will also support the tumor aspect."

"The company is evaluated as being sensitive to global trends, effectively managing risks, and proactively responding to market changes. It fosters a research-friendly environment by collaborating with various research teams to promote technological innovation. Additionally, the Oncostudio program being used at Wonju Severance Christian Hospital is highly user-friendly and well-automated, enabling various clinical applications. I am optimistic about the future of Oncosoft and expect it to continue expanding its global network and leading innovation."

"Three main features of OncoStudio that our hospital loves are: Firstly, its remarkable contouring precision, including excellent depiction of organs at risk (OAR) and breast PTV. Secondly, its use of DICOM transfer method ensures seamless compatibility with diverse equipment, alleviating concerns about interoperability. Thirdly, its advanced automatic region recognition technology simplifies workflow by not requiring meticulous attention to DICOM header descriptions, enhancing efficiency."

"In recent years, data-driven accurate and precise treatment has been increasingly emphasized in the field of radiation therapy. AI technology has also made significant advancements, particularly in the field of auto-segmentation, aiding in accurately separating tumors and normal tissues to establish safe treatment plans. Oncostudio, a product of Oncosoft used at Yonsei Cancer Hospital, has gained competitiveness as a global AI-based software company through collaboration with an excellent development team and Yonsei Cancer Hospital."